Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.
Status:
Completed
Trial end date:
2020-03-23
Target enrollment:
Participant gender:
Summary
The aim of the study is to determine if treatment for recently acquired hepatitis C infection
(with or without HIV coinfection) can be shortened when treating with the interferon-free
therapy sofosbuvir/velpatasvir (SOF/VEL).
SOF/VEL is a new treatment for hepatitis C called direct acting antiviral which targets the
hepatitis C virus replication cycle and has been shown in phase II studies in chronic HCV to
be highly effective (SVR12 >95%) when given for 12 weeks.
Data has shown that treatment can be shortened when treating recently acquired HCV with
interferon containing treatments. It is not known whether treatment with SOF/VEL can be
shortened.
This study aims to find out if treatment for 6 weeks with open-label SOF/VEL is equivalent to
treatment for 12 weeks with SOF/VEL in participants with recently acquired hepatitis C
infection. The project is a randomised study where both participants and investigators would
not find out the treatment duration of the participants until week 6 of treatment.